Status:
COMPLETED
Recombinant Factor VIIa in Acute Intracerebral Haemorrhage
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Acquired Bleeding Disorder
Intracerebral Haemorrhage
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
This trial is conducted in Asia, Europe, Middle East, North America, Oceania, and South America. The purpose of this study is to evaluate the treatment of Recombinant Factor VIIa (eptacog alfa (activ...
Eligibility Criteria
Inclusion
- Spontaneous intracranial hemorrhage (ICH) within 3 hours after first symptom
Exclusion
- Patients with secondary ICH
- Pre-existing disability
- Haemophilia
Key Trial Info
Start Date :
May 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2007
Estimated Enrollment :
829 Patients enrolled
Trial Details
Trial ID
NCT00127283
Start Date
May 1 2005
End Date
January 1 2007
Last Update
January 12 2017
Active Locations (167)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Investigational Site
Birmingham, Alabama, United States, 35209
2
Novo Nordisk Investigational Site
Mobile, Alabama, United States, 36617
3
Novo Nordisk Investigational Site
Phoenix, Arizona, United States, 85013
4
Novo Nordisk Investigational Site
Fort Smith, Arkansas, United States, 72901